12.09.19
CTD is also a proud sponsor of the NPUK Annual Family Conference & Interactive Workshop on Niemann-Pick Diseases, for the 4th year running...
Read more12.09.19
Evidera, a research group working on behalf of Sanofi Genzyme, is conducting a research study to understand the symptoms and impact experienced by carers of those affected by ASMD Niemann-Pick disease types B, or A/B...
Read more30.08.19
Copenhagen, Denmark, August 28, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights...
Read more26.07.19
We are pleased to inform you of a study opportunity available to NPC patients and their families:
Clinical Outcomes Solutions (COS), is a research company conducting research into Niemann-Pick type C (NPC) on behalf of a sponsor, Orphazyme A/S, a pharmaceutical company studying NPC...
22.07.19
Following the encouraging regulatory agency feedback, Orphazyme plans to introduce an Early Access
Program for NPC in the fall of 2019, to further accelerate access to treatment with arimoclomol for people
living with NPC...